<DOC>
	<DOCNO>NCT00313846</DOCNO>
	<brief_summary>The objective study demonstrate effectiveness tolerability buprenorphine transdermal system ( BTDS ) ( 5 , 10 20 ) comparison placebo transdermal system subject moderate severe osteoarthritis pain hip knee currently treat oral opioids . The double-blind treatment intervention duration 4 week time supplemental analgesic medication ( acetaminophen ) provide subject addition study drug .</brief_summary>
	<brief_title>Safety Efficacy Buprenorphine Transdermal System Subjects With Moderate Severe Osteoarthritis Hip Knee</brief_title>
	<detailed_description>Buprenorphine synthetic opioid analgesic 25 year international clinical experience indicate safe effective variety therapeutic situation relief moderate severe pain .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>clinical diagnosis chronic osteoarthritis hip knee 1 year longer . average pain due osteoarthritis moderate , moderatelysevere , severe 14 day prior enrollment . ingest opioid analgesic daily basis . ingest &gt; 2500 milligram ( mg ) acetaminophen daily basis . require &lt; 20 mg &gt; 80 mg morphine ( opioid equivalent ) per day control osteoarthritis pain . Other protocolspecific exclusion/inclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Chronic pain</keyword>
	<keyword>opioid</keyword>
	<keyword>transdermal</keyword>
	<keyword>osteoarthritis</keyword>
</DOC>